Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Molecular pathways and management options in RCC

Marston Linehan • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer Antibodies Bevacizumab Erlotinib

Marston Linehan, MD, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses the molecular pathways and management options in non-clear cell renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Marston Linehan

4:39
Clear cell RCC: VHL/HIF pathway
Marston Linehan • 13 Feb 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals